Ignite Creation Date:
2024-05-06 @ 3:33 PM
Last Modification Date:
2024-10-26 @ 1:52 PM
Study NCT ID:
NCT04674774
Status:
UNKNOWN
Last Update Posted:
2022-02-10
First Post:
2020-12-14
Brief Title:
Efficacy of Tegoprazan Based Bismuth Quadruple Therapy for Helicobacter Pylori Infection
Sponsor:
Incheon StMarys Hospital
Organization:
Incheon StMarys Hospital
Study Overview
Official Title:
Efficacy of Tegoprazan Based Bismuth Quadruple Therapy Compared With Bismuth Quadruple Therapy for Helicobacter Pylori Infection Randomized Double-blind Active-Controlled Study
Status:
UNKNOWN
Status Verified Date:
2022-01
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to investigate eradication rate drug compliance and adverse events in patients with confirmed Helicobacter pylori infection between tegoprazan bismuth metronidazole and tetracycline for 14 days TBMT and PPI bismuth metronidazole and tetracycline for 14 days LBMT
Detailed Description:
This is a multi-center double-blind randomized active-controlled study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None